Resource Type

Journal Article 208

Conference Videos 5

Year

2024 1

2023 19

2022 26

2021 21

2020 17

2019 12

2018 18

2017 14

2016 6

2015 14

2014 6

2013 10

2012 5

2011 6

2010 11

2009 4

2008 6

2007 9

2002 1

2000 1

open ︾

Keywords

molecular dynamics 9

targeted therapy 8

molecular dynamics simulation 6

cancer 4

drug resistance 4

China 3

Molecular dynamics simulation 3

molecular classification 3

molecular docking 3

molecular epidemiology 3

molecular markers 3

Alzheimer’s disease 2

Graphene 2

Machine learning 2

Molecular dynamics 2

Synthesis 2

Vaccine 2

cancer therapy 2

drug delivery 2

open ︾

Search scope:

排序： Display mode:

Molecular classification and molecular targeted therapy of cancer

Miao Xu, Jianyong Shao, Yixin Zeng

Frontiers of Medicine 2013, Volume 7, Issue 2,   Pages 147-149 doi: 10.1007/s11684-013-0274-2

HTML PDF Collect

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 245-255 doi: 10.1007/s11684-009-0044-3

Abstract: Over the last decade, molecular genetic abnormalities have been described in NSCLC, including chromosomalThese molecular markers in NSCLC demonstrated close associations with the development of lung cancerTherefore, this information may be applied for early cancer detection, classification, novel targetedTherefore, it is very important to select NSCLC patients with biomarkers to match targeted agents sothat we can further identify effectiveness of targeted therapy in the future.

Keywords： lung cancer     carcinoma     non-small cell lung cancer     molecular markers     targeted therapy    

HTML PDF Collect

Molecular targeted therapy of gynecological malignant tumors: the development and challenge, from laboratory

Pengming SUN PhD, MD , Jalid SEHOULI PhD, MD , Lihui WEI BM ,

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 256-264 doi: 10.1007/s11684-009-0052-3

Abstract: More and more molecular drugs based on targeted therapy have been utilized in the treatment of gynecologicIn this article, we systematically review the current targeted therapeutic trials running in clinic.Other planned or ongoing trials currentlytargeted at molecular markers which may play important rolesin gynecological carcinogenesis andprogression suggest that combination chemotherapy with moleculartargeted therapy will ultimately be an importantoption.

Keywords： target therapy     gynecologic malignant tumors     clinical trail     molecular medicine    

HTML PDF Collect

Translational medicine in hepatocellular carcinoma

Qiang Gao, Yinghong Shi, Xiaoying Wang, Jian Zhou, Shuangjian Qiu, Jia Fan

Frontiers of Medicine 2012, Volume 6, Issue 2,   Pages 122-133 doi: 10.1007/s11684-012-0193-7

Abstract: In the past decade, tremendous progress has been achieved in the molecular stratification of HCCs forTo date, the molecular classification of HCCs has been carried out through transcriptomic, genetic andSuch research has led to identification of several potential molecular targets in HCC, and subsequentlyIn this article, we review the current knowledge of the molecular pathogenesis of HCC and outline potentialimmunotherapy and strategies targeting various components of the tumor microenvironment, as well as novel molecular

Keywords： hepatocellular carcinoma     molecular classification     molecular targeted therapies     tumor microenvironment    

HTML PDF Collect

Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging

Liangqian Tong, Ming Zhao, Shu Zhu, Jing Chen

Frontiers of Medicine 2011, Volume 5, Issue 4,   Pages 379-387 doi: 10.1007/s11684-011-0162-6

Abstract: Superparamagnetic iron oxide (SPIO) nanoparticles have become a popular strategy of cancer treatment and molecularstudies have shown the exciting potential of functionalized SPIO nanoparticles, such as surface-coated, targetedligand-conjugated, and/or drug-loaded SPIO nanoparticles, as powerful tools for targeted imaging andprimarily concentrate on the recent advancements in the field of SPIO nanoparticles in terms of synthesis, targeted

Keywords： nanoparticles     superparamagnetic iron oxide     targeted therapy     molecular imaging     cancer    

HTML PDF Collect

Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis

Yue Yu, Jie He

Frontiers of Medicine 2013, Volume 7, Issue 2,   Pages 157-171 doi: 10.1007/s11684-013-0272-4

Abstract: Molecular biology techniques, particularly gene expression microarrays, proteomics, and next-generationsequencing, have recently been developed to facilitate effectively its molecular classification.The underlying etiology, pathogenesis, therapeutics, and prognosis of NSCLC based on an improved molecularThis review focuses on the molecular classification of NSCLC based on gene expression microarray technology

Keywords： non-small-cell lung cancer     molecular typing     individualized medicine     molecular-targeted therapy     gene expression    

HTML PDF Collect

Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies

Peter B. Alexander,Xiao-Fan Wang

Frontiers of Medicine 2015, Volume 9, Issue 2,   Pages 134-138 doi: 10.1007/s11684-015-0396-9

Abstract:

Drug resistance is a major factor that limits the efficacy of targeted cancer therapies.mechanisms of resistance to receptor tyrosine kinase inhibitors, which are the most prevalent class of targeted

Keywords： targeted therapy     drug resistance     receptor tyrosine kinases     cancer    

HTML PDF Collect

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 689-700 doi: 10.1007/s11684-020-0759-8

Abstract: Further improvement in outcome will need to rely more heavily on molecular therapeutic as well as immunoThere are other fusions or mutations that may serve as putative targets, but effective targeted therapyWith the expanding therapeutic armamentarium, we should start focus on rational combinations of targeted

Keywords： acute lymphoblastic leukemia     molecular therapeutics     targeted therapy     tyrosine kinase inhibitors     immunotherapy    

HTML PDF Collect

Molecular network-based intervention brings us closer to ending the HIV pandemic

Xiaoxu Han, Bin Zhao, Minghui An, Ping Zhong, Hong Shang

Frontiers of Medicine 2020, Volume 14, Issue 2,   Pages 136-148 doi: 10.1007/s11684-020-0756-y

Abstract: HIV molecular networks can be determined by phylogenetic approach, genetic distance-based approach, andpopulations, reconstruct the history of HIV spread, monitor the dynamics of HIV transmission, guide targetedSimulation and retrospective studies have demonstrated that these molecular network-based interventionsHowever, we still need to address several challenges to improve the practice of molecular network-guidedIn addition, molecular and social networks must be combined, and technical parameters and ethnic issues

Keywords： human immunodeficiency virus type 1     molecular cluster     transmission cluster     risk network     targeted intervention    

HTML PDF Collect

A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma

Frontiers of Medicine 2023, Volume 17, Issue 2,   Pages 275-289 doi: 10.1007/s11684-022-0945-y

Abstract: The abnormal activation of HER family kinase activity is closely related to the development of human malignancies. In this study, we used HER kinases as targets for the treatment of nasopharyngeal carcinoma (NPC) and explored the anti-tumor effects of the novel pan-HER inhibitor HM781-36B, alone or in combination with cisplatin. We found that HER family proteins were positively expressed in tumor tissues of some NPC patients, and the high levels of those proteins were significantly related to poor prognosis. HM781-36B inhibited NPC in vitro and in vivo. HM781-36B exerted synergistic effects with cisplatin on inhibiting proliferation and promoting apoptosis of NPC cells. In NPC xenograft models in nude mice, HM781-36B and cisplatin synergistically inhibited tumor growth. Downregulating the activity of HER family proteins and their downstream signaling pathways and regulating tumor microenvironment may explain the synergistic anti-tumor effects of HM781-36B and cisplatin. In conclusion, our study provides evidence for HER family proteins as prognostic biomarkers and potential therapeutic targets for NPC. The pan-HER inhibitor HM781-36B alone or in combination with cisplatin represents promising therapeutic effects for the treatment of NPC patients, which provides a new idea for the comprehensive treatment of NPC.

Keywords： epidermal growth factor receptor     ErbB receptors     HM781-36B     nasopharyngeal carcinoma     molecular targeted    

HTML PDF Collect

Influence of Survivin-targeted siRNA on the biological features of colorectal carcinoma cells

XIONG Ying, GUO Wen, LI Ting, LI Ke

Frontiers of Medicine 2007, Volume 1, Issue 3,   Pages 304-307 doi: 10.1007/s11684-007-0058-7

Abstract: The transient transfection of survivin-targeted siRNA to Lovo cells and its influence on the biologicalTwo pairs of 19 base pairs (bp) siRNA-specific targeted survivin gene were designed and synthesized byAfter transient transfection of the two survivin-targeted siRNAs to Lovo cells by Lipofectamine™ 2000Based on the results, we can draw a conclusion that the two survivin-targeted siRNAs successfully suppressed

Keywords： control     therapy     influence     Survivin-1     colorectal carcinoma    

HTML PDF Collect

A Double-Layer Polysaccharide Hydrogel (DPH) for the Enhanced Intestine-Targeted Oral Delivery of Probiotics

Wen-Can Huang,Wenjie Wang,Wei Wang,Yanan Hao,Changhu Xue,Xiangzhao Mao,

Engineering doi: 10.1016/j.eng.2023.05.024

Abstract: This double-layer structure allows DPH to encapsulate and deliver probiotics in a targeted manner withinThus, DPH endows probiotics with excellent intestine-targeted delivery, improved oral bioavailability

Keywords： Polysaccharides     Chitosan     Hydrogels     Oral delivery     Intestine-targeted    

HTML PDF Collect

Progress and challenges in RET-targeted cancer therapy

Frontiers of Medicine 2023, Volume 17, Issue 2,   Pages 207-219 doi: 10.1007/s11684-023-0985-y

Abstract: The rearranged during transfection (RET) is a receptor protein tyrosine kinase. Oncogenic RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and in thyroid cancer, but also increasingly in various types of cancers at low rates. In the last few years, two potent and selective RET protein tyrosine kinase inhibitors (TKIs), pralsetinib (BLU-667) and selpercatinib (LOXO-292, LY3527723) were developed and received regulatory approval. Although pralsetinib and selpercatinib gave high overall response rates (ORRs), < 10% of patients achieved a complete response (CR). The RET TKI-tolerated residual tumors inevitably develop resistance by secondary target mutations, acquired alternative oncogenes, or MET amplification. RET G810 mutations located at the kinase solvent front site were identified as the major on-target mechanism of acquired resistance to both selpercatinib and pralsetinib. Several next-generation of RET TKIs capable of inhibiting the selpercatinib/pralsetinib-resistant RET mutants have progressed to clinical trials. However, it is likely that new TKI-adapted RET mutations will emerge to cause resistance to these next-generation of RET TKIs. Solving the problem requires a better understanding of the multiple mechanisms that support the RET TKI-tolerated persisters to identify a converging point of vulnerability to devise an effective co-treatment to eliminate the residual tumors.

Keywords： pralsetinib     selpercatinib     RET-alteration     lung cancer     thyroid cancer     tumor-agnostic therapy     drug resistance    

HTML PDF Collect

Microwave-induced high-energy sites and targeted energy transition promising for efficient energy deployment

Frontiers in Energy 2022, Volume 16, Issue 6,   Pages 931-942 doi: 10.1007/s11708-021-0771-y

Abstract: In this study, a high-energy-site phenomenon and targeted-energy transition mechanism were identifiedThe whole process, including microwave energy concentration and intense site-energy release, shapes a targeted-energyThe microwave-induced high-energy sites and targeted energy transition provide an important pathway for

Keywords： microwave discharge     high-energy sites     targeted-energy transition     morphology design     energy efficiency    

HTML PDF Collect

Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy

Frontiers of Medicine 2023, Volume 17, Issue 3,   Pages 493-502 doi: 10.1007/s11684-022-0946-x

Abstract: heterogeneity (ITH) has been proven to contribute to the poor treatment response and the resistance to targetedwhether the variant allele frequencies (VAFs) of ALK fusions can help assess ITH and predict targetedALK VAF determined by hybrid capture-based NGS is probably unreliable for ITH assessment and targeted

Keywords： situ hybridization     immunohistochemistry     variant allele frequency     intratumoral heterogeneity     targeted    

HTML PDF Collect

Title Author Date Type Operation

Molecular classification and molecular targeted therapy of cancer

Miao Xu, Jianyong Shao, Yixin Zeng

Journal Article

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Journal Article

Molecular targeted therapy of gynecological malignant tumors: the development and challenge, from laboratory

Pengming SUN PhD, MD , Jalid SEHOULI PhD, MD , Lihui WEI BM ,

Journal Article

Translational medicine in hepatocellular carcinoma

Qiang Gao, Yinghong Shi, Xiaoying Wang, Jian Zhou, Shuangjian Qiu, Jia Fan

Journal Article

Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging

Liangqian Tong, Ming Zhao, Shu Zhu, Jing Chen

Journal Article

Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis

Yue Yu, Jie He

Journal Article

Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies

Peter B. Alexander,Xiao-Fan Wang

Journal Article

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Journal Article

Molecular network-based intervention brings us closer to ending the HIV pandemic

Xiaoxu Han, Bin Zhao, Minghui An, Ping Zhong, Hong Shang

Journal Article

A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma

Journal Article

Influence of Survivin-targeted siRNA on the biological features of colorectal carcinoma cells

XIONG Ying, GUO Wen, LI Ting, LI Ke

Journal Article

A Double-Layer Polysaccharide Hydrogel (DPH) for the Enhanced Intestine-Targeted Oral Delivery of Probiotics

Wen-Can Huang,Wenjie Wang,Wei Wang,Yanan Hao,Changhu Xue,Xiangzhao Mao,

Journal Article

Progress and challenges in RET-targeted cancer therapy

Journal Article

Microwave-induced high-energy sites and targeted energy transition promising for efficient energy deployment

Journal Article

Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy

Journal Article